Volociximab Biosimilar – Anti-ITGA5, CD49e mAb – Research Grade

Introduction

Volociximab is a monoclonal antibody that targets the alpha 5 subunit of integrin, specifically known as ITGA5 or CD49e. This biosimilar antibody, also referred to as anti-ITGA5 or CD49e mAb, has shown promising potential as a therapeutic agent in various diseases due to its unique structure and activity. In this article, we will delve deeper into the structure, activity, and potential applications of Volociximab Biosimilar – Anti-ITGA5, CD49e mAb – Research Grade.

Structure of Volociximab Biosimilar

Volociximab is a recombinant humanized IgG1 monoclonal antibody, meaning it is derived from human cells and has been modified to have a structure similar to natural human antibodies. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The variable region of the antibody, responsible for binding to its target, is highly specific for the alpha 5 subunit of integrin. This specific binding site allows Volociximab to selectively target and bind to ITGA5, making it a potent therapeutic agent.

Activity of Volociximab Biosimilar

As mentioned earlier, Volociximab specifically targets the alpha 5 subunit of integrin, which plays a crucial role in cell adhesion and migration. Integrins are a family of cell surface receptors that mediate cell-cell and cell-matrix interactions. The alpha 5 subunit, when paired with the beta 1 subunit, forms the fibronectin receptor, which is involved in various cellular processes such as cell adhesion, migration, and proliferation. By binding to ITGA5, Volociximab inhibits the function of this receptor, leading to a decrease in cell adhesion and migration. This activity has been shown to have therapeutic potential in various diseases, as discussed below.

Applications of Volociximab Biosimilar

Volociximab has been studied in various diseases, with promising results in preclinical and clinical trials. Some potential applications of this antibody include:

Cancer Integrins, specifically the alpha 5 subunit, are overexpressed in many types of cancer and are associated with tumor growth, invasion, and metastasis. By targeting ITGA5, Volociximab has shown to inhibit tumor growth and metastasis in preclinical studies. In a phase II clinical trial, Volociximab in combination with standard chemotherapy showed promising results in patients with advanced non-small cell lung cancer, leading to improved overall survival.

Fibrotic diseases

Fibrosis is a pathological process characterized by excessive accumulation of scar tissue in organs, leading to organ dysfunction. Integrins play a crucial role in fibrosis by promoting the migration and activation of fibroblasts, the cells responsible for producing scar tissue. By targeting ITGA5, Volociximab has shown to inhibit fibroblast migration and reduce fibrosis in preclinical studies. It has potential as a therapeutic agent for diseases such as idiopathic pulmonary fibrosis and liver fibrosis.

Inflammatory diseases

Integrins also play a role in inflammation by promoting the migration of immune cells to sites of inflammation. In preclinical studies, Volociximab has shown to reduce inflammation in diseases such as rheumatoid arthritis and inflammatory bowel disease. It has the potential to be used as a treatment for these and other inflammatory diseases.

Other potential applications

Volociximab has also shown potential in other diseases such as diabetic nephropathy, retinal diseases, and cardiovascular diseases. Further research is needed to explore its potential in these and other conditions.

Conclusion

In summary, Volociximab Biosimilar – Anti-ITGA5, CD49e mAb – Research Grade is a promising therapeutic agent with a unique structure and activity. By targeting the alpha